The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs. The antibody offers the potential to prevent blood clots without the bleeding risks associated with currently available anticoagulants.
The post Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots appeared first on MedCity News.
Leave a comment